Aachen (Germany), 28 October 2006 - Biopharmaceutical company PAION AG (FSE: PA8) today announced that the independent Data Monitoring Committee (DMC) for the DIAS-2 Phase III study met and informed the Steering Committee, PAION and its development partner for Desmoteplase, Forest Laboratories, Inc. (New York, USA), that it has reviewed the cumulative data from the study provided by the Companies and recommended to resume patient enrolment into DIAS-2 with no modification of the protocol. At this meeting, the DMC reviewed data from 170 randomized patients. The DIAS-2 study is evaluating PAION's drug candidate Desmoteplase in patients with acute ischaemic stroke. The Companies continue to expect that enrolment will be completed by the end of 2006 and that study results will be available by the middle of 2007.
Contact Dr. Peer Nils Schroeder, Investor Relations / Public Relations PAION AG Martinstrasse 10-12 52062 Aachen - Germany Tel. +49 (0)241 4453 152 Email [email protected] www.paion.de
--- End of Ad-hoc Message --- WKN: A0B65S; ISIN: DE000A0B65S3; Index: Prime All Share, CDAX; Listed: Prime Standard in Frankfurter Wertpapierbörse, Amtlicher Markt in Frankfurter Wertpapierbörse, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Stuttgart;
